High-dose lung radiation: a quicker path to tumor control?

NCT ID NCT01803542

Recruiting now Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study is testing stereotactic body radiation therapy (SBRT) for people with non-small cell lung cancer or other cancers that have spread to the lung. Instead of daily radiation for weeks, participants receive high doses in just 3 to 10 sessions over 1 to 2 weeks. The goal is to see how well this approach controls tumors and improves survival, while tracking side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Stereotactic body radiation therapy (SBRT)
What this could lead to: If successful, this could provide a more effective, shorter radiation treatment option for lung tumors, potentially improving cancer control and survival.
What could go wrong: This is a mid-stage trial with 200 participants, so results are not yet proven. Side effects from high-dose radiation are possible, and the approach may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTASIS FROM OTHER CANCERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer metastatic neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTASIS FROM OTHER CANCERS NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Princess Margaret Hospital, University Health Network
RECRUITING

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.